Do elevated neural autoantibodies indicate clinically meaningful immune recognition?

Neural autoantibodies can be informative markers of immune reactivity, but their diagnostic meaning is not inherent in an “elevated” result. Interpretation is strongest when the laboratory signal, antigen, syndrome, and neurologic investigations converge.

Clinical and assay evidence

• In a cohort of 1,228 patients, serum cell-based-assay positive predictive values for several neural antibodies ranged from 69.7% to 91.8%; with tissue-based confirmation, they increased to 94.3%–100%. Thus, complementary confirmation can materially distinguish clinically meaningful reactivity from isolated assay positivity.
• Specimen choice is antibody-dependent: CSF is generally more sensitive for NMDAR and GFAP antibodies, while serum may be more sensitive for LGI1 and CASPR2. A positive result should therefore be judged against the appropriate testing modality and the syndrome expected for that antibody.
• Symptoms and neurologic corroboration are essential. In encephalitis-mimicking disorders, 61.9% of positive antibody results were considered nonspecific, often when another diagnosis better explained the presentation. Conversely, a negative panel does not exclude autoimmune encephalitis if the phenotype and supporting investigations remain convincing.

Mechanistic interpretation

• Antibodies against defined targets, such as D1/D2 receptor epitopes or MAG, are plausibly evidence of immune recognition. However, ELISA-based binding may reflect peptide/non-native epitope recognition or cross-reactivity rather than binding to the native antigen in nervous tissue.
• Panel-level positivity in 32% of healthy controls in one study, cutoff-dependent weak anti-MAG positives, and incompletely defined anti-microglial targets illustrate why low-level or isolated results do not establish pathogenicity.

Bottom line

• Elevated neural autoantibodies are not diagnoses. They become clinically meaningful when confirmed by an appropriate assay, interpreted according to antibody-specific serum/CSF performance, and aligned with a compatible neurologic syndrome and corroborating evaluation.